T1	Drug 24 35	gemcitabine
T2	Drug 37 48	carboplatin
T3	Drug 86 94	Iniparib
T4	Temporal 3 8	Prior
*	OR T1 T2 T3
T5	Scope 24 94	gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib
R1	Has_temporal Arg1:T5 Arg2:T4	
T6	Condition 127 135	neoplasm
T7	Condition 198 222	non-melanoma skin cancer
T8	Procedure 190 197	treated
T9	Qualifier 190 197	treated
R2	multi Arg1:T9 Arg2:T8	
R3	Has_qualifier Arg1:T7 Arg2:T9	
T10	Condition 226 243	carcinoma in-situ
T11	Condition 277 284	cancers
T12	Qualifier 268 276	invasive
R4	Has_qualifier Arg1:T11 Arg2:T12	
T13	Qualifier 285 305	treated definitively
T14	Procedure 285 292	treated
R5	multi Arg1:T13 Arg2:T14	
R6	Has_qualifier Arg1:T11 Arg2:T13	
*	OR T7 T10 T11
T15	Negation 168 189	with the exception of
T16	Temporal 329 348	>5 years previously
T17	Observation 356 379	evidence of recurrences
T18	Negation 353 355	no
R7	Has_negation Arg1:T17 Arg2:T18	
T19	Observation 116 123	history
T20	Temporal 108 115	current
T21	Temporal 100 104	Past
*	OR T20 T21
T22	Scope 100 115	Past or current
R8	Has_temporal Arg1:T6 Arg2:T19	
T23	Qualifier 136 166	other than the entry diagnosis
T24	Condition 151 166	entry diagnosis
R9	multi Arg1:T23 Arg2:T24	
R10	Has_qualifier Arg1:T6 Arg2:T23	
T25	Scope 190 379	treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences
R11	Has_temporal Arg1:T14 Arg2:T16	
R12	Has_negation Arg1:T25 Arg2:T15	
T26	Condition 398 413	cardiac disease
T27	Observation 387 394	history
R13	Has_temporal Arg1:T26 Arg2:T27	
T28	Parsing_Error 415 428	as defined by
T29	Condition 431 453	Malignant hypertension
T30	Condition 455 470	Unstable angina
T31	Condition 472 496	Congestive heart failure
T32	Condition 498 519	Myocardial infarction
T33	Temporal 520 548	within the previous 6 months
R14	Has_temporal Arg1:T32 Arg2:T33	
T34	Condition 589 608	cardiac arrhythmias
T35	Qualifier 575 587	uncontrolled
T36	Qualifier 563 571	unstable
T37	Qualifier 550 561	Symptomatic
*	OR T35 T36 T37
T38	Scope 550 587	Symptomatic, unstable or uncontrolled
R15	Has_scope Arg1:T34 Arg2:T38	
T39	Condition 652 671	atrial fibrillation
T40	Grammar_Error 672 684	are eligible
T41	Negation 672 684	are eligible
R16	Has_negation Arg1:T39 Arg2:T41	
T42	Qualifier 636 651	rate-controlled
T43	Qualifier 628 634	stable
R17	Has_qualifier Arg1:T39 Arg2:T42	
R18	Has_qualifier Arg1:T39 Arg2:T43	
T44	Condition 718 734	brain metastases
T45	Temporal 711 717	Active
R19	Has_temporal Arg1:T44 Arg2:T45	
T46	Condition 758 774	brain metastases
T47	Procedure 750 757	treated
T48	Qualifier 750 757	treated
R20	multi Arg1:T48 Arg2:T47	
R21	Has_qualifier Arg1:T46 Arg2:T48	
T49	Negation 775 787	are eligible
T50	Grammar_Error 775 787	are eligible
T51	Procedure 796 813	radiation therapy
T52	Temporal 828 865	at least 2 weeks prior to study entry
T53	Reference_point 854 865	study entry
R23	Has_index Arg1:T52 Arg2:T53	
T54	Condition 895 914	disease progression
T55	Procedure 871 885	follow-up scan
T56	Negation 892 894	no
R24	Has_negation Arg1:T54 Arg2:T56	
R25	AND Arg1:T55 Arg2:T54	
T57	Drug 949 957	steroids
T58	Negation 937 940	not
T59	Mood 941 948	require
R26	Has_mood Arg1:T57 Arg2:T59	
R27	Has_negation Arg1:T57 Arg2:T58	
R28	Has_temporal Arg1:T51 Arg2:T52	
T60	Scope 796 957	radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids
T61	Scope 750 774	treated brain metastases
A1	Optional T61
R22	Has_scope Arg1:T61 Arg2:T60	
T62	Scope 750 957	treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids
R29	Has_negation Arg1:T62 Arg2:T49	
T63	Condition 977 985	pregnant
T64	Person 963 968	Women
T65	Condition 989 998	lactating
*	OR T65 T63
T66	Pregnancy_considerations 963 998	Women who are pregnant or lactating
T67	Condition 1024 1033	infection
T68	Value 1035 1044	> Grade 2
T69	Qualifier 1035 1044	> Grade 2
R30	multi Arg1:T69 Arg2:T68	
R31	Has_qualifier Arg1:T67 Arg2:T69	
T70	Qualifier 1008 1015	serious
T71	Temporal 1017 1023	active
R32	Has_temporal Arg1:T67 Arg2:T71	
R33	Has_qualifier Arg1:T67 Arg2:T70	
T72	Condition 1097 1114	medical condition
T73	Qualifier 1078 1085	serious
T74	Subjective_judgement 1008 1015	serious
T75	Subjective_judgement 1078 1085	serious
R34	Has_qualifier Arg1:T72 Arg2:T73	
T76	Post-eligibility 1076 1190	A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
T77	Condition 1126 1189	impair the ability of the patient to receive protocol treatment
T78	Mood 1120 1125	would
R35	Has_mood Arg1:T77 Arg2:T78	
R36	AND Arg1:T72 Arg2:T77	
T79	Procedure 1203 1221	surgical procedure
T80	Qualifier 1197 1202	major
T81	Subjective_judgement 1197 1202	major
R37	Has_qualifier Arg1:T79 Arg2:T80	
T82	Qualifier 1226 1237	significant
T83	Subjective_judgement 1226 1237	significant
T84	Condition 1238 1254	traumatic injury
T85	Temporal 1255 1286	â‰¤28 days of beginning treatment
T86	Reference_point 1267 1286	beginning treatment
R38	multi Arg1:T85 Arg2:T86	
R39	Has_qualifier Arg1:T84 Arg2:T82	
R40	Has_temporal Arg1:T84 Arg2:T85	
T87	Procedure 1320 1333	major surgery
T88	Mood 1311 1319	need for
R41	Has_mood Arg1:T87 Arg2:T88	
T89	Temporal 1334 1364	during the course of the study
T90	Reference_point 1341 1364	the course of the study
R42	multi Arg1:T89 Arg2:T90	
R43	Has_temporal Arg1:T87 Arg2:T89	
*	OR T87 T84 T79
T91	Qualifier 1370 1382	Uncontrolled
T92	Temporal 1386 1398	intercurrent
T93	Condition 1399 1406	illness
T94	Qualifier 1423 1480	in the opinion of the investigator may increase the risks
T95	Subjective_judgement 1423 1480	in the opinion of the investigator may increase the risks
R44	Has_qualifier Arg1:T93 Arg2:T94	
*	OR T92 T91
T96	Scope 1370 1398	Uncontrolled or intercurrent
R45	Has_scope Arg1:T93 Arg2:T96	
T97	Post-eligibility 1367 1629	9. Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results.
T98	Condition 1661 1682	psychiatric condition
T99	Condition 1686 1708	laboratory abnormality
T100	Procedure 1686 1696	laboratory
R46	multi Arg1:T99 Arg2:T100	
*	OR T99 T98
T101	Post-eligibility 1635 1926	History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.
T102	Condition 1959 1975	hypersensitivity
T103	Condition 1951 1958	allergy
*	OR T102 T103
T104	Mood 1932 1937	Known
T105	Mood 1941 1950	suspected
*	OR T105 T104
T106	Scope 1932 1950	Known or suspected
T107	Drug 1983 2022	agent given in the course of this trial
T108	Scope 1951 1975	allergy/hypersensitivity
R47	AND Arg1:T108 Arg2:T107	
R48	Has_scope Arg1:T108 Arg2:T106	
T109	Post-eligibility 1932 2022	Known or suspected allergy/hypersensitivity to any agent given in the course of this trial
T110	Not_a_criteria 2025 2161	The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
